Complete Stage 1 dose escalation for INNATE monotherapy
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Monotherapy Solid Tumors 1H 2021 Stage 1: Dose Escalation All Comers”
What we found
Evidence strength A What the grades mean
The company completed the monotherapy dose escalation in July 2021, which is after the first half of 2021 deadline.
-
A Jounce Therapeutics, Inc. 10-K filed 2022-03-02
“In January 2021, we began enrollment in the dose-escalation portion of the INNATE trial and enrollment was completed in July and October 2021 for monotherapy and combination therapy, respectively.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Complete
- Deliverable
- Stage 1 dose escalation
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Jounce Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C640455-021842 · Corrections policy